Hisashi Uhara

Dr. Hisashi Uhara

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
THTokimasa Hida
Tokimasa Hida
TKTakafumi Kamiya
Takafumi Kamiya
AKAkinori Kawakami
Akinori Kawakami
JOJiro Ogino
Jiro Ogino
馬相馬仁 相
馬仁 相
KJKowichi Jimbow
Kowichi Jimbow
Melanogenesis is the biological and biochemical process of melanin and melanosome biosynthesis. Melanin is formed by enzymic reactions of tyrosinase family proteins that convert tyrosine to form brown-black eumelanin and yellow-red pheomelanin within melanosomal compartments in melanocytes, following the cascades of events interacting with a series of autocrine and paracrine signals. Fully melanized melanosomes are delivered to keratinocytes of the skin and hair. The symbiotic relation of a melanocyte and an associated pool of keratinocytes is called epidermal melanin unit (EMU). Microphthalmia-associated transcription factor (MITF) plays a vital role in melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes for promoting melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis. Diseases involving alterations of EMU show various forms of pigmentation phenotypes. This review introduces four major topics of melanogenesis cascade that include (1) melanocyte development and differentiation, (2) melanogenesis and intracellular trafficking for melanosome biosynthesis, (3) melanin pigmentation and pigment-type switching, and (4) development of a novel therapeutic approach for malignant melanoma by elucidation of melanogenesis cascade.

24 April 2024 in European Journal of Cancer
Verified
Journal Article
Open access
Claus GarbeClaus Garbe
Claus Garbe
AFAna-Maria Forsea
Ana-Maria Forsea
TATeresa Amaral
Teresa Amaral
PAPetr Arenberger
Petr Arenberger
PAPhilippe Autier
Philippe Autier
LBLieve Brochez
Lieve Brochez
Cancers of the skin are the most commonly occurring cancers in humans. In fair-skinned populations, up to 95% of keratinocyte skin cancers and 70-95% of cutaneous melanomas are caused by ultraviolet radiation and are thus theoretically preventable. Currently, however, there is no comprehensive global advice on practical steps to be taken to reduce the toll of skin cancer. To address this gap, an expert working group comprising clinicians and researchers from Africa, America, Asia, Australia, and Europe, together with learned societies (European Association of Dermato-Oncology, Euromelanoma, Euroskin, European Union of Medical Specialists, and the Melanoma World Society) reviewed the extant evidence and issued the following evidence-based recommendations for photoprotection as a strategy to prevent skin cancer. Fair skinned people, especially children, should minimise their exposure to ultraviolet radiation, and are advised to use protective measures when the UV index is forecast to reach 3 or higher. Protective measures include a combination of seeking shade, physical protection (e.g. clothing, hat, sunglasses), and applying broad-spectrum, SPF 30 + sunscreens to uncovered skin. Intentional exposure to solar ultraviolet radiation for the purpose of sunbathing and tanning is considered an unhealthy behaviour and should be avoided. Similarly, use of solaria and other artificial sources of ultraviolet radiation to encourage tanning should be strongly discouraged, through regulation if necessary. Primary prevention of skin cancer has a positive return on investment. We encourage policymakers to communicate these messages to the general public and promote their wider implementation.

1 December 2018 in European Journal of Cancer
Verified
Journal Article
Open access
KNKenjiro Namikawa
Kenjiro Namikawa
YKYoshio Kiyohara
Yoshio Kiyohara
TTTatsuya Takenouchi
Tatsuya Takenouchi
HUHisashi Uhara
Hisashi Uhara
HUHiroshi Uchi
Hiroshi Uchi
NYNaoya Yamazaki
Naoya Yamazaki
The aim of the study was to evaluate the efficacy and safety of nivolumab combined with ipilimumab in treatment-naïve Japanese patients with advanced melanoma. In this multicentre, single-arm study, treatment-naïve Japanese patients with unresectable stage III/IV or recurrent melanoma received nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks for four doses, followed by biweekly doses of nivolumab (3 mg/kg). The primary end-point was centrally assessed objective response rate (ORR). Secondary end-points included overall survival (OS), progression-free survival (PFS), disease control rate and safety. The subtypes of the thirty patients enrolled were: 12, mucosal; eight, non-acral cutaneous; seven, acral; two, uveal and one, unknown primary melanoma. The ORR was 43.3% (95% confidence interval [CI]: 25.5, 62.6) with central and local assessment. The centrally and locally assessed disease control rate (95% CI) were 73.3% (54.1, 87.7) and 86.7% (69.3, 96.2), respectively. At the median follow-up period of 14.1 months (range 5.2-27.7), median OS and centrally assessed PFS were not reached. OS (95% CI) at 6, 12, 18 and 24 months was 93.3% (75.9, 98.3), 83.3% (64.5, 92.7), 72.9% (50.0, 86.5) and 65.6% (40.4, 82.2), respectively. Treatment-related adverse events (AEs) occurred in all patients. Grade III-IV and serious AEs occurred, mostly during the combination phase, in 23 (76.7%) and 20 (66.7%) patients, respectively. No treatment-related deaths occurred. This study confirmed the efficacy and safety of nivolumab plus ipilimumab in treatment-naïve Japanese patients with advanced melanoma including rare subtypes. Incidence rates for grade III-IV AEs were high but manageable with appropriate medical attention and treatment. JapicCTI-152869.

1 June 1990 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
THTomohide Hoshikawa
Tomohide Hoshikawa
TNTakashi Nakajima
Takashi Nakajima
HUHisashi Uhara
Hisashi Uhara
MGMasahiro Gotoh
Masahiro Gotoh
YSYukio Shimosato
Yukio Shimosato
SESatoshi Ebihara
Satoshi Ebihara

1 June 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KKKeiju Kobayashi
Keiju Kobayashi
RKRyuta Kamekura
Ryuta Kamekura
JKJunji Kato
Junji Kato
SKShiori Kamiya
Shiori Kamiya
TKTakafumi Kamiya
Takafumi Kamiya
HUHisashi Uhara
Hisashi Uhara

4 December 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
TMTomoyuki Minowa
Tomoyuki Minowa
KMKenji Murata
Kenji Murata
YMYuka Mizue
Yuka Mizue
AMAiko Murai
Aiko Murai
MNMunehide Nakatsugawa
Munehide Nakatsugawa
Toshihiko TorigoeToshihiko Torigoe
Toshihiko Torigoe
Acral lentiginous melanoma (ALM) is the most common melanoma subtype in non-Caucasians. Despite advances in cancer immunotherapy, current immune checkpoint inhibitors remain unsatisfactory for ALM. Hence, we conducted comprehensive immune profiling using single-cell phenotyping with reactivity screening of the T cell receptors of tumor-infiltrating T lymphocytes (TILs) in ALM. Compared with cutaneous melanoma, ALM showed a lower frequency of tumor-reactive CD8 clusters and an enrichment of regulatory T cells with direct tumor recognition ability, suggesting a suppressive immune microenvironment in ALM. Tumor-reactive CD8 TILs showed heterogeneous expression of coinhibitory molecules, including KLRC1 (NKG2A), in subpopulations with therapeutic implications. Overall, our study provides a foundation for enhancing the efficacy of immunotherapy in ALM.